Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04869137 · ClinicalTrials.gov registry record · Phase 2

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

A Phase 2 study of Merkel Cell Carcinoma and Neuroendocrine Carcinoma of the Skin, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Active
Registry status
Phase 2
Development phase
26
Enrollment target
1
Study location

NCT04869137 is a Phase 2 study of Merkel Cell Carcinoma and Neuroendocrine Carcinoma of the Skin that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 26 participants, below the 50-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04869137, a Phase 2 study of Merkel Cell Carcinoma and Neuroendocrine Carcinoma of the Skin, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.

Conditions Studied

Merkel Cell Carcinoma Neuroendocrine Carcinoma of the Skin Trabecular Carcinoma of the Skin

Interventions

  • DRUG Pembrolizumab
  • DRUG Lenvatinib Oral Product

Study Locations (1)

Florida

  • Moffitt Cancer Center - Tampa

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2021-05-28
Est. Completion 2026-09
Phase Phase 2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04869137

The ClinicalTrials.gov registry entry for NCT04869137 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 50-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (48% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Merkel Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT04869137 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT04869137 about?

NCT04869137 is a clinical study titled "Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma". This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.

What is the current status of trial NCT04869137?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2021-05-28. Estimated completion is 2026-09.

What conditions does trial NCT04869137 study?

This clinical trial studies the following conditions: Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin.

What interventions are being tested in trial NCT04869137?

The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib Oral Product (DRUG).

Who is sponsoring clinical trial NCT04869137?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04869137 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Merkel Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Merkel Cell Carcinoma

All registered trials for this condition

Neuroendocrine Carcinoma of the Skin

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.